| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 34 | 2024 | 2887 | 2.650 |
Why?
|
| Genetic Predisposition to Disease | 27 | 2024 | 2270 | 1.890 |
Why?
|
| Germ-Line Mutation | 13 | 2023 | 329 | 1.540 |
Why?
|
| Genetic Testing | 16 | 2024 | 535 | 1.140 |
Why?
|
| Biomarkers, Tumor | 12 | 2021 | 1464 | 1.020 |
Why?
|
| BRCA2 Protein | 10 | 2024 | 158 | 0.970 |
Why?
|
| Elasticity Imaging Techniques | 5 | 2021 | 59 | 0.930 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2019 | 137 | 0.720 |
Why?
|
| BRCA1 Protein | 8 | 2023 | 200 | 0.710 |
Why?
|
| Antineoplastic Agents | 10 | 2023 | 2358 | 0.700 |
Why?
|
| Ovarian Neoplasms | 7 | 2023 | 744 | 0.690 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 288 | 0.690 |
Why?
|
| Drugs, Investigational | 2 | 2016 | 37 | 0.680 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2016 | 98 | 0.640 |
Why?
|
| Female | 63 | 2024 | 44509 | 0.620 |
Why?
|
| Prognosis | 9 | 2021 | 3675 | 0.600 |
Why?
|
| Humans | 90 | 2024 | 86617 | 0.590 |
Why?
|
| Stroke | 2 | 2023 | 965 | 0.570 |
Why?
|
| Aged | 35 | 2023 | 18402 | 0.570 |
Why?
|
| Neoplasms | 11 | 2023 | 2898 | 0.550 |
Why?
|
| Checkpoint Kinase 2 | 5 | 2023 | 23 | 0.530 |
Why?
|
| Genes, BRCA2 | 5 | 2023 | 160 | 0.510 |
Why?
|
| Middle Aged | 39 | 2022 | 25017 | 0.500 |
Why?
|
| Drug Screening Assays, Antitumor | 5 | 2018 | 78 | 0.490 |
Why?
|
| Ultrasonography, Mammary | 4 | 2022 | 82 | 0.470 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2017 | 456 | 0.450 |
Why?
|
| Case-Control Studies | 14 | 2021 | 1804 | 0.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2019 | 1197 | 0.430 |
Why?
|
| Adult | 34 | 2022 | 25640 | 0.420 |
Why?
|
| Gene Expression Profiling | 6 | 2021 | 1384 | 0.410 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 5 | 2023 | 13 | 0.400 |
Why?
|
| Recombinational DNA Repair | 2 | 2021 | 9 | 0.390 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2021 | 156 | 0.390 |
Why?
|
| Microbiota | 4 | 2021 | 381 | 0.380 |
Why?
|
| Lung Neoplasms | 3 | 2018 | 2262 | 0.360 |
Why?
|
| Aged, 80 and over | 16 | 2021 | 6501 | 0.360 |
Why?
|
| Pancreatic Neoplasms | 3 | 2020 | 645 | 0.350 |
Why?
|
| Genetic Variation | 6 | 2022 | 1351 | 0.340 |
Why?
|
| Mutation | 13 | 2021 | 3967 | 0.340 |
Why?
|
| Skin | 3 | 2018 | 554 | 0.320 |
Why?
|
| Thrombosis | 2 | 2021 | 296 | 0.320 |
Why?
|
| Prospective Studies | 12 | 2022 | 4212 | 0.310 |
Why?
|
| Multifactorial Inheritance | 2 | 2019 | 159 | 0.300 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 1075 | 0.300 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 4 | 2023 | 52 | 0.300 |
Why?
|
| DNA-Binding Proteins | 4 | 2023 | 1208 | 0.300 |
Why?
|
| Cell Line, Tumor | 9 | 2023 | 2426 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 189 | 0.280 |
Why?
|
| Receptor, ErbB-2 | 2 | 2019 | 223 | 0.280 |
Why?
|
| Young Adult | 14 | 2021 | 5974 | 0.270 |
Why?
|
| Pyridones | 2 | 2023 | 51 | 0.270 |
Why?
|
| Precision Medicine | 3 | 2020 | 395 | 0.260 |
Why?
|
| HIV-1 | 3 | 2019 | 163 | 0.260 |
Why?
|
| Genes, BRCA1 | 3 | 2021 | 192 | 0.260 |
Why?
|
| HIV Infections | 3 | 2019 | 772 | 0.250 |
Why?
|
| Machado-Joseph Disease | 1 | 2023 | 8 | 0.230 |
Why?
|
| Rivaroxaban | 1 | 2023 | 12 | 0.230 |
Why?
|
| Receptors, Estrogen | 3 | 2021 | 384 | 0.230 |
Why?
|
| Erythrocytes | 2 | 2021 | 255 | 0.230 |
Why?
|
| Dabigatran | 1 | 2023 | 24 | 0.230 |
Why?
|
| Male | 26 | 2023 | 40958 | 0.230 |
Why?
|
| Hip Fractures | 1 | 2023 | 45 | 0.230 |
Why?
|
| DNA Repair Enzymes | 2 | 2020 | 52 | 0.230 |
Why?
|
| Reproducibility of Results | 8 | 2023 | 2705 | 0.230 |
Why?
|
| Osteoporotic Fractures | 1 | 2023 | 38 | 0.220 |
Why?
|
| Biosensing Techniques | 1 | 2023 | 68 | 0.220 |
Why?
|
| Thrombectomy | 2 | 2021 | 158 | 0.220 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 3636 | 0.220 |
Why?
|
| Risk Factors | 10 | 2023 | 5417 | 0.220 |
Why?
|
| Registries | 3 | 2021 | 702 | 0.220 |
Why?
|
| Genetic Association Studies | 3 | 2020 | 294 | 0.220 |
Why?
|
| Breast Density | 2 | 2019 | 31 | 0.220 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2023 | 73 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2021 | 2357 | 0.210 |
Why?
|
| Warfarin | 1 | 2023 | 103 | 0.210 |
Why?
|
| Cohort Studies | 8 | 2021 | 2767 | 0.210 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 532 | 0.210 |
Why?
|
| Genome-Wide Association Study | 4 | 2021 | 1621 | 0.210 |
Why?
|
| Skilled Nursing Facilities | 1 | 2022 | 41 | 0.210 |
Why?
|
| Alcoholism | 1 | 2023 | 172 | 0.210 |
Why?
|
| Fractals | 1 | 2021 | 42 | 0.210 |
Why?
|
| Treatment Outcome | 9 | 2022 | 7990 | 0.210 |
Why?
|
| Leuprolide | 1 | 2021 | 30 | 0.210 |
Why?
|
| Apraxias | 1 | 2021 | 2 | 0.200 |
Why?
|
| Research Design | 2 | 2023 | 594 | 0.200 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2018 | 70 | 0.200 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2021 | 6 | 0.200 |
Why?
|
| Mammography | 2 | 2022 | 461 | 0.200 |
Why?
|
| Abdominal Fat | 1 | 2021 | 13 | 0.200 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 481 | 0.200 |
Why?
|
| Administration, Oral | 1 | 2023 | 684 | 0.200 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 1673 | 0.200 |
Why?
|
| Carcinoma, Lobular | 1 | 2021 | 80 | 0.190 |
Why?
|
| MicroRNAs | 2 | 2016 | 534 | 0.190 |
Why?
|
| Elasticity | 1 | 2021 | 94 | 0.190 |
Why?
|
| Metformin | 1 | 2022 | 128 | 0.190 |
Why?
|
| Speech | 1 | 2021 | 84 | 0.190 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 150 | 0.190 |
Why?
|
| Oligopeptides | 1 | 2021 | 179 | 0.190 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2020 | 18 | 0.190 |
Why?
|
| Risk Assessment | 5 | 2023 | 2261 | 0.190 |
Why?
|
| Patient Positioning | 1 | 2021 | 63 | 0.190 |
Why?
|
| Mutation, Missense | 4 | 2024 | 276 | 0.190 |
Why?
|
| Neuroimaging | 1 | 2021 | 113 | 0.190 |
Why?
|
| Thromboembolism | 1 | 2021 | 119 | 0.180 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 376 | 0.180 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2019 | 3 | 0.180 |
Why?
|
| Tomography, Optical Coherence | 1 | 2020 | 130 | 0.180 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2021 | 69 | 0.180 |
Why?
|
| Anticoagulants | 1 | 2023 | 408 | 0.180 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2019 | 25 | 0.180 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 2 | 2016 | 21 | 0.180 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 378 | 0.180 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2019 | 425 | 0.180 |
Why?
|
| Patient Discharge | 1 | 2022 | 300 | 0.180 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2016 | 44 | 0.180 |
Why?
|
| Quality Control | 2 | 2017 | 117 | 0.170 |
Why?
|
| Viremia | 1 | 2019 | 54 | 0.170 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2019 | 35 | 0.170 |
Why?
|
| Trastuzumab | 1 | 2019 | 68 | 0.170 |
Why?
|
| Urinary Bladder | 1 | 2021 | 246 | 0.170 |
Why?
|
| Models, Statistical | 2 | 2016 | 574 | 0.170 |
Why?
|
| Plasmids | 2 | 2016 | 287 | 0.170 |
Why?
|
| Caspase 8 | 1 | 2018 | 34 | 0.170 |
Why?
|
| Insulin Resistance | 1 | 2021 | 377 | 0.170 |
Why?
|
| HIV Protease | 1 | 2018 | 10 | 0.160 |
Why?
|
| Sensitivity and Specificity | 5 | 2022 | 1991 | 0.160 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 391 | 0.160 |
Why?
|
| Emollients | 1 | 2018 | 2 | 0.160 |
Why?
|
| Anti-HIV Agents | 2 | 2013 | 149 | 0.160 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 167 | 0.160 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2018 | 100 | 0.160 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 1204 | 0.160 |
Why?
|
| Macrophages | 1 | 2021 | 554 | 0.160 |
Why?
|
| NADPH Oxidase 1 | 1 | 2017 | 1 | 0.160 |
Why?
|
| Patient Admission | 1 | 2018 | 112 | 0.150 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2017 | 15 | 0.150 |
Why?
|
| Interleukin-13 | 1 | 2017 | 36 | 0.150 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2017 | 10 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 468 | 0.150 |
Why?
|
| Hospitals | 1 | 2020 | 294 | 0.150 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2016 | 182 | 0.150 |
Why?
|
| Family | 1 | 2019 | 311 | 0.150 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 108 | 0.150 |
Why?
|
| Valine | 1 | 2017 | 69 | 0.150 |
Why?
|
| Cell Cycle Proteins | 2 | 2017 | 388 | 0.150 |
Why?
|
| Interleukin-4 | 1 | 2017 | 127 | 0.150 |
Why?
|
| Algorithms | 4 | 2019 | 1830 | 0.150 |
Why?
|
| Malassezia | 1 | 2016 | 1 | 0.150 |
Why?
|
| Dermatomycoses | 1 | 2016 | 8 | 0.150 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 61 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 2 | 2016 | 297 | 0.150 |
Why?
|
| Drug Therapy | 1 | 2017 | 70 | 0.140 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2017 | 93 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2016 | 3 | 0.140 |
Why?
|
| Artificial Intelligence | 2 | 2011 | 298 | 0.140 |
Why?
|
| Disease Progression | 1 | 2021 | 1531 | 0.140 |
Why?
|
| Nitrophenols | 1 | 2016 | 11 | 0.140 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2016 | 19 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 746 | 0.140 |
Why?
|
| Brain Ischemia | 1 | 2021 | 398 | 0.140 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 165 | 0.140 |
Why?
|
| Puberty | 1 | 2016 | 59 | 0.140 |
Why?
|
| Oncogene Protein v-akt | 1 | 2016 | 21 | 0.140 |
Why?
|
| Biphenyl Compounds | 1 | 2016 | 68 | 0.140 |
Why?
|
| Gene Expression | 2 | 2021 | 1284 | 0.140 |
Why?
|
| Lymph Nodes | 1 | 2020 | 530 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 381 | 0.140 |
Why?
|
| Endometrial Neoplasms | 1 | 2018 | 193 | 0.140 |
Why?
|
| Phosphotransferases | 1 | 2015 | 65 | 0.140 |
Why?
|
| Isoindoles | 1 | 2015 | 14 | 0.130 |
Why?
|
| Inflammation | 1 | 2021 | 920 | 0.130 |
Why?
|
| Medical History Taking | 3 | 2021 | 80 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 257 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 279 | 0.130 |
Why?
|
| Reference Standards | 1 | 2016 | 159 | 0.130 |
Why?
|
| Breast | 3 | 2022 | 286 | 0.130 |
Why?
|
| Hedgehog Proteins | 1 | 2015 | 93 | 0.130 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2015 | 46 | 0.130 |
Why?
|
| Genotype | 4 | 2021 | 1851 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 262 | 0.130 |
Why?
|
| Histones | 1 | 2017 | 311 | 0.130 |
Why?
|
| Epidemiologic Research Design | 1 | 2014 | 22 | 0.130 |
Why?
|
| Piperazines | 1 | 2016 | 272 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2015 | 589 | 0.120 |
Why?
|
| Obesity | 1 | 2021 | 963 | 0.120 |
Why?
|
| Benzamides | 1 | 2015 | 229 | 0.120 |
Why?
|
| Biological Specimen Banks | 1 | 2014 | 65 | 0.120 |
Why?
|
| Paclitaxel | 1 | 2016 | 460 | 0.120 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2015 | 214 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2016 | 300 | 0.120 |
Why?
|
| Retrospective Studies | 6 | 2023 | 8477 | 0.120 |
Why?
|
| Machine Learning | 1 | 2016 | 232 | 0.120 |
Why?
|
| Biomarkers | 4 | 2022 | 1718 | 0.120 |
Why?
|
| Sarcoma | 1 | 2015 | 212 | 0.120 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2013 | 3 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2018 | 689 | 0.120 |
Why?
|
| Signal Transduction | 4 | 2018 | 3241 | 0.120 |
Why?
|
| Odds Ratio | 3 | 2021 | 678 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 1169 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 1169 | 0.110 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 151 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 696 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1373 | 0.110 |
Why?
|
| Exome | 1 | 2013 | 127 | 0.110 |
Why?
|
| Body Mass Index | 3 | 2021 | 770 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 556 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2016 | 645 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 864 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2022 | 1565 | 0.110 |
Why?
|
| Adolescent | 6 | 2021 | 8979 | 0.110 |
Why?
|
| Heterozygote | 2 | 2023 | 365 | 0.110 |
Why?
|
| Erythropoietin | 1 | 2012 | 91 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2013 | 129 | 0.100 |
Why?
|
| Microvessels | 2 | 2022 | 70 | 0.100 |
Why?
|
| Quinazolines | 1 | 2013 | 220 | 0.100 |
Why?
|
| Apoptosis | 1 | 2018 | 1683 | 0.100 |
Why?
|
| Dermatitis, Atopic | 1 | 2012 | 52 | 0.100 |
Why?
|
| Probability | 1 | 2012 | 355 | 0.100 |
Why?
|
| Metagenome | 1 | 2012 | 102 | 0.100 |
Why?
|
| Logistic Models | 3 | 2021 | 1185 | 0.100 |
Why?
|
| Body Weight | 1 | 2012 | 459 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 3 | 2021 | 853 | 0.100 |
Why?
|
| United States | 5 | 2021 | 6665 | 0.100 |
Why?
|
| Oxygen Consumption | 2 | 2021 | 239 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 1721 | 0.090 |
Why?
|
| Models, Biological | 2 | 2019 | 1749 | 0.090 |
Why?
|
| Area Under Curve | 2 | 2020 | 334 | 0.090 |
Why?
|
| Computer Simulation | 3 | 2020 | 1078 | 0.090 |
Why?
|
| Age of Onset | 2 | 2021 | 310 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 552 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 1019 | 0.080 |
Why?
|
| DNA, Neoplasm | 2 | 2021 | 265 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2018 | 1538 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2023 | 858 | 0.080 |
Why?
|
| Risk | 2 | 2021 | 674 | 0.080 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 2 | 2017 | 8 | 0.080 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2017 | 30 | 0.080 |
Why?
|
| RNA Helicases | 2 | 2017 | 35 | 0.080 |
Why?
|
| Virus Replication | 2 | 2019 | 319 | 0.080 |
Why?
|
| Cell Movement | 1 | 2011 | 758 | 0.080 |
Why?
|
| Genomics | 3 | 2017 | 720 | 0.070 |
Why?
|
| Internet | 2 | 2020 | 312 | 0.070 |
Why?
|
| Drug Resistance, Viral | 1 | 2007 | 51 | 0.070 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 392 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 2436 | 0.070 |
Why?
|
| Melanoma | 1 | 2011 | 454 | 0.070 |
Why?
|
| Decision Making | 1 | 2012 | 642 | 0.070 |
Why?
|
| Oxidative Stress | 2 | 2021 | 447 | 0.070 |
Why?
|
| Workflow | 2 | 2017 | 77 | 0.070 |
Why?
|
| Alleles | 2 | 2021 | 1128 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2021 | 839 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 1753 | 0.060 |
Why?
|
| Databases, Genetic | 2 | 2018 | 260 | 0.060 |
Why?
|
| Learning | 1 | 2007 | 280 | 0.060 |
Why?
|
| Germ Cells | 1 | 2024 | 126 | 0.060 |
Why?
|
| Computational Biology | 2 | 2017 | 528 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 1961 | 0.060 |
Why?
|
| Sitagliptin Phosphate | 1 | 2022 | 3 | 0.060 |
Why?
|
| Liraglutide | 1 | 2022 | 5 | 0.060 |
Why?
|
| Insulin Glargine | 1 | 2022 | 9 | 0.060 |
Why?
|
| Age Factors | 2 | 2018 | 1849 | 0.060 |
Why?
|
| Sulfonylurea Compounds | 1 | 2022 | 64 | 0.050 |
Why?
|
| Survival Rate | 2 | 2020 | 1860 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 879 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2023 | 314 | 0.050 |
Why?
|
| Bone Density | 1 | 2023 | 209 | 0.050 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2021 | 17 | 0.050 |
Why?
|
| Neurobiology | 1 | 2021 | 10 | 0.050 |
Why?
|
| Cerebellum | 1 | 2023 | 247 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2021 | 71 | 0.050 |
Why?
|
| Mitochondria, Muscle | 1 | 2021 | 26 | 0.050 |
Why?
|
| Anisotropy | 1 | 2021 | 62 | 0.050 |
Why?
|
| tau Proteins | 1 | 2021 | 62 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2021 | 34 | 0.050 |
Why?
|
| Supine Position | 1 | 2021 | 30 | 0.050 |
Why?
|
| Physical Fitness | 1 | 2021 | 51 | 0.050 |
Why?
|
| Ethanol | 1 | 2023 | 249 | 0.050 |
Why?
|
| Cell Count | 1 | 2021 | 195 | 0.050 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2021 | 67 | 0.050 |
Why?
|
| Everolimus | 1 | 2021 | 40 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2021 | 36 | 0.050 |
Why?
|
| Fibrin | 1 | 2021 | 84 | 0.050 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 62 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2023 | 267 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2017 | 1578 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 138 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 190 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2022 | 894 | 0.050 |
Why?
|
| Radiation Dosage | 1 | 2021 | 227 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 408 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2023 | 319 | 0.050 |
Why?
|
| Carboplatin | 1 | 2021 | 286 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2021 | 153 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2021 | 140 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2019 | 66 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2015 | 1981 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 93 | 0.040 |
Why?
|
| Pancreas | 1 | 2021 | 239 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2021 | 473 | 0.040 |
Why?
|
| Reference Values | 1 | 2020 | 674 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 162 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 66 | 0.040 |
Why?
|
| Child | 3 | 2016 | 6926 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2021 | 329 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2020 | 185 | 0.040 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 132 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2021 | 695 | 0.040 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2019 | 42 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 98 | 0.040 |
Why?
|
| Comamonadaceae | 1 | 2018 | 2 | 0.040 |
Why?
|
| Proteobacteria | 1 | 2018 | 6 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2601 | 0.040 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2018 | 19 | 0.040 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2018 | 54 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2022 | 329 | 0.040 |
Why?
|
| ROC Curve | 1 | 2021 | 752 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 317 | 0.040 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 90 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2019 | 196 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2020 | 429 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2018 | 77 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 873 | 0.040 |
Why?
|
| Smokers | 1 | 2018 | 41 | 0.040 |
Why?
|
| DNA | 1 | 2024 | 1294 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2021 | 449 | 0.040 |
Why?
|
| Mice | 3 | 2019 | 11352 | 0.040 |
Why?
|
| MRE11 Homologue Protein | 1 | 2017 | 2 | 0.040 |
Why?
|
| Exercise | 1 | 2021 | 315 | 0.040 |
Why?
|
| Neurofibromin 1 | 1 | 2017 | 8 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 11 | 0.040 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2017 | 13 | 0.040 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2017 | 33 | 0.040 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2017 | 23 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 683 | 0.040 |
Why?
|
| Mass Screening | 1 | 2022 | 617 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2018 | 237 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 740 | 0.040 |
Why?
|
| Cytokines | 1 | 2021 | 776 | 0.040 |
Why?
|
| Prevalence | 1 | 2021 | 1239 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 56 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 104 | 0.040 |
Why?
|
| Retreatment | 1 | 2017 | 107 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2017 | 40 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 576 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2018 | 91 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2017 | 65 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 1056 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2018 | 256 | 0.040 |
Why?
|
| Sebaceous Glands | 1 | 2016 | 28 | 0.040 |
Why?
|
| Aging | 1 | 2021 | 691 | 0.040 |
Why?
|
| DNA Barcoding, Taxonomic | 1 | 2016 | 11 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 1823 | 0.040 |
Why?
|
| Biodiversity | 1 | 2018 | 197 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2018 | 677 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3357 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2015 | 9 | 0.030 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2015 | 20 | 0.030 |
Why?
|
| Software | 1 | 2020 | 654 | 0.030 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2015 | 14 | 0.030 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2015 | 23 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 56 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 166 | 0.030 |
Why?
|
| Aurora Kinases | 1 | 2015 | 17 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 143 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2015 | 41 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2015 | 46 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 458 | 0.030 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2015 | 33 | 0.030 |
Why?
|
| Glycosylation | 1 | 2015 | 129 | 0.030 |
Why?
|
| beta Catenin | 1 | 2017 | 251 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 220 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2015 | 72 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 120 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 1204 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2015 | 111 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2015 | 103 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 273 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 113 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 700 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 270 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 369 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 480 | 0.030 |
Why?
|
| Genome | 1 | 2017 | 372 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2015 | 179 | 0.030 |
Why?
|
| Bacteria | 1 | 2018 | 447 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 185 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 484 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 736 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2015 | 325 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 266 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 916 | 0.030 |
Why?
|
| Anorexia | 1 | 2013 | 30 | 0.030 |
Why?
|
| Drug Costs | 1 | 2013 | 62 | 0.030 |
Why?
|
| Neurons | 1 | 2021 | 1546 | 0.030 |
Why?
|
| Animals | 3 | 2019 | 26582 | 0.030 |
Why?
|
| Staphylococcus | 1 | 2012 | 24 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2012 | 17 | 0.030 |
Why?
|
| Diarrhea | 1 | 2013 | 182 | 0.030 |
Why?
|
| Patient Selection | 1 | 2015 | 685 | 0.030 |
Why?
|
| Base Sequence | 1 | 2015 | 2330 | 0.030 |
Why?
|
| RNA, Bacterial | 1 | 2012 | 108 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2013 | 237 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 307 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 3045 | 0.030 |
Why?
|
| S Phase | 1 | 2011 | 62 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2012 | 241 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 2378 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 1937 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 999 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2011 | 94 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 296 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2012 | 217 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 236 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2011 | 250 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 434 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 255 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2011 | 790 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2012 | 355 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 5209 | 0.020 |
Why?
|
| Quality of Life | 1 | 2014 | 1583 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 3611 | 0.020 |
Why?
|
| Hypertension | 1 | 2013 | 1141 | 0.020 |
Why?
|